Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 3/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.38 |
| ▸ | OGA | O60502 | 8/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | MET | P08581 | 1/20 | 0.36 |
| ▸ | CLK2 | P49760 | 1/20 | 0.36 |
| ▸ | CLK3 | P49761 | 1/20 | 0.36 |
| ▸ | DRD4 | P21917 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.34 |
| ▸ | TAB1 | Q15750 | 1/20 | 0.34 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23038642 | 0.95 | HRH3 (0.37) | HRH3GSK3BDYRK1AOGAKDM4E | |
| SCHEMBL22635529 | 0.84 | OGA (0.33) | OGAALDH1A1DRD4SIGMAR1MAPT | |
| SCHEMBL1558099 | 0.84 | SIRT6 (0.40) | GSK3BDYRK1AALDH1A1CLK2CLK3 | |
| SCHEMBL174612 | 0.83 | F2 (0.41) | ALDH1A1TDP1DRD4SIGMAR1MAPT | |
| SCHEMBL16196214 | 0.81 | MEN1 (0.42) | GSK3BDYRK1AALDH1A1DRD4SIGMAR1 | |
| SCHEMBL22648384 | 0.81 | ALDH1A1 (0.40) | GSK3BDYRK1AALDH1A1METDRD4 | |
| SCHEMBL16975385 | 0.81 | ACHE (0.45) | ALDH1A1MAPT | |
| SCHEMBL16974776 | 0.81 | ACHE (0.42) | ALDH1A1DRD4SIGMAR1MAPT | |
| SCHEMBL29258453 | 0.80 | ALDH1A1 (0.34) | HRH3KDM4EALDH1A1TDP1MAPT | |
| SCHEMBL2184349 | 0.80 | MAP3K7 (0.49) | ALDH1A1METMAP3K7TAB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260042750-A1 | HETEROARYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS LLC (US) | 2026-02-12 | — | — | US | disclosed |
| US-12479833-B2 | Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof | DECIPHERA PHARMACEUTICALS, LLC (US) | 2025-11-25 | — | — | US | disclosed |
| CN-114072397-B | Heteroaryl aminopyrimidinamide autophagy inhibitors and methods of use thereof | 德西费拉制药有限责任公司 | 2025-03-28 | — | — | CN | disclosed |
| EP-4295846-A2 | HETEROARYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | Deciphera Pharmaceuticals, LLC (US) | 2023-12-27 | — | — | EP | disclosed |
| EP-3966206-B1 | HETEROARYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS LLC (US) | 2023-08-09 | — | — | EP | disclosed |
| EP-3966206-B1 | HETEROARYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS LLC (US) | 2023-08-09 | — | — | EP | disclosed |
| US-20230047915-A1 | HETEROARYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2023-02-16 | — | — | US | disclosed |
| US-20230047915-A1 | HETEROARYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2023-02-16 | — | — | US | disclosed |
| US-11518758-B2 | Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof | DECIPHERA PHARMACEUTICALS, LLC (US) | 2022-12-06 | — | — | US | disclosed |
| US-11518758-B2 | Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof | DECIPHERA PHARMACEUTICALS, LLC (US) | 2022-12-06 | — | — | US | disclosed |
| US-11479555-B2 | Substituted 1,2-dihydro-3H-pyrazolo[3,4-D]pyrimidin-3-ones as inhibitors of WEE-1 kinase | NEWAVE PHARMACEUTICAL INC. (US) | 2022-10-25 | — | — | US | disclosed |
| US-11390611-B2 | — | — | 2022-07-19 | — | — | US | disclosed |
| EP-3966206-A1 | HETEROARYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | Deciphera Pharmaceuticals, LLC (US) | 2022-03-16 | — | — | EP | disclosed |
| CN-114072397-A | Heteroaryl aminopyrimidine amide autophagy inhibitors and methods of use thereof | 德西费拉制药有限责任公司 | 2022-02-18 | — | — | CN | disclosed |
| US-20210061807-A1 | 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDINE-3-ONE COMPOUNDS AS INHIBITORS OF WEE-1 KINASE | NEWAVE PHARMACEUTICAL INC. | 2021-03-04 | — | — | US | disclosed |
| US-20200354346-A1 | HETEROARYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2020-11-12 | — | — | US | disclosed |
| US-20200354346-A1 | HETEROARYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2020-11-12 | — | — | US | disclosed |
| WO-2019165204-A1 | 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDINE-3-ONE COMPOUNDS AS INHIBITORS OF WEE-1 KINASE | NEWAVE PHARMACEUTICAL INC. (US) | 2019-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210061807-A1 | 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDINE-3-ONE COMPOUNDS AS INHIBITORS OF WEE-1 KINASE | WEE1, WEE2, PEAK1 | HRH3 1512/4885GSK3B 535/4885DYRK1A 301/4885 |
| US-20230047915-A1 | HETEROARYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | BECN1, SQSTM1, ATG7 | HRH3 2287/4885GSK3B 1474/4885DYRK1A 2573/4885 |
| US-12479833-B2 | Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof | BECN1, SQSTM1, ATG7 | HRH3 2287/4885GSK3B 1474/4885DYRK1A 2573/4885 |
| US-11479555-B2 | Substituted 1,2-dihydro-3H-pyrazolo[3,4-D]pyrimidin-3-ones as inhibitors of WEE-1 kinase | WEE1, WEE2, PHKG1 | HRH3 1435/4885GSK3B 562/4885DYRK1A 301/4885 |
| US-11390611-B2 | — | BECN1, TFEB, SQSTM1 | HRH3 3939/4885GSK3B 681/4885DYRK1A 4232/4885 |
| US-20200354346-A1 | HETEROARYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | BECN1, SQSTM1, ATG7 | HRH3 2287/4885GSK3B 1474/4885DYRK1A 2573/4885 |
| US-11518758-B2 | Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof | BECN1, SQSTM1, ATG7 | HRH3 2287/4885GSK3B 1474/4885DYRK1A 2573/4885 |
| US-20260042750-A1 | HETEROARYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | BECN1, ATG7, SQSTM1 | HRH3 1704/4885GSK3B 362/4885DYRK1A 2426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.